Cited by Using Passive Antibody Therapies in the Next Pandemic

Clinical outcomes in immunocompromised adults with COVID-19, based on anti-spike IgG serostatus and monoclonal antibody therapy: a retrospective cohort study in the Omicron period DOI

Shilpa Vasishta, Judith A. Aberg, Gopi Patel

et al.

Therapeutic Advances in Infectious Disease, Journal Year: 2025, Volume and Issue: 12

Published: Jan. 1, 2025

Background: Immunocompromised adults may experience severe COVID-19 outcomes, necessitating a multifaceted treatment approach. Studies from the Delta period showed benefit monoclonal antibody (mAb) therapy that was most pronounced among anti-spike IgG seronegative individuals. With widespread vaccination and shifting SARS-CoV-2 variants in Omicron period, clinical predictors of seronegativity, impacts on remain incompletely characterized. Objectives: We describe outcomes cohort immunocompromised with stratified by serostatus receipt mAb during to evaluate impact. Design: This retrospective study mild-moderate presenting between December 2021 October 2022. Methods: Charts were reviewed assess serostatus, therapy, 28-day including conventional oxygen use, high-flow mechanical ventilation, death. Results: A total 276 individuals included, whom 252 (91%) partially or fully vaccinated, 190 (69%) seropositive, 225 (82%) received therapy. majority solid organ transplant recipients (169, 61%), seronegatively significantly associated mycophenolate-based immunosuppression comorbid chronic kidney disease. Conventional use seropositive patients receiving mAb, not 2/154 (1%), 5/71 (7%), 6/36 (17%), 4/15 (27%), respectively. Across cohort, death occurred 6 (2%), 4 (3%), 3 (1%) individuals, Conclusion: Clinical predominantly mild–moderate appeared vary Observed trends would prospective studies future iterations therapeutics inform decisions for adults.

Language: Английский

Citations

Accurate evaluation of live-virus microneutralisation for SARS-CoV-2 variant JN.1 in the assessment of vaccination and therapeutics DOI

Giulia Dowgier,

Agnieszka Hobbs,

David Greenwood

et al.

Vaccine, Journal Year: 2025, Volume and Issue: 54, P. 126960 - 126960

Published: March 7, 2025

Language: Английский

Citations

Replication Features of SARS-CoV-2 and Advantages of Targeting S Protein with Aptamers to Block Viral Entry DOI

Jun Zheng,

Qiuxia Pang,

Zhaoying Fu

et al.

ACS Omega, Journal Year: 2025, Volume and Issue: unknown

Published: April 21, 2025

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a virus of the coronaviridae family. The enters cell through binding to corresponding receptor angiotensin-converting enzyme (ACE2) on host membrane with spike protein (S protein) its envelope; thus, we can design inhibitors that bind S block entry into cells. Aptamers are single stranded DNA or RNA molecules form specific three-dimensional structures and their target high affinity specificity thus promising candidates for inhibitors. This paper reviews replication cycle mechanisms SARS-CoV-2 as well preparation principle characteristics aptamers, features discussion advantages using aptamers prevent from infecting cells, finally summarizes research progress in protein-blocking aptamers.

Language: Английский

Citations

Using Passive Antibody Therapies in the Next Pandemic DOI

Nigel Paneth, Michael J. Joyner,

A. Casadevall

et al.

Current topics in microbiology and immunology, Journal Year: 2024, Volume and Issue: unknown

Published: Jan. 1, 2024

Language: Английский

Citations